CAR-T Proteins From Sino Biologicals
CAR-T cell therapy, a groundbreaking cancer treatment, has a history of over 60 years of research. It originated from the discovery of bone marrow transplantation in the 1950s and the use of antibodies as guides for T cells in the early 1900s. The development of chimeric antigen receptors (CARs) in 1987 paved the way for CAR-T cells to target tumors. In 2017, historic approvals were granted for CAR-T therapies, including Tisagenlecleucel and Axicabtagene ciloleucel. Since then, several CAR-T cell therapies have achieved worldwide approvals, revolutionizing cancer treatment. Despite challenges, CAR-T therapy shows immense potential for improving human health.
Sino Biological offers a range of fluorescent-labeled target proteins that can be directly used in CAR detection, providing a more efficient method compared to secondary antibody cross-reactions that can cause background staining. These fluorescent-labeled proteins have high bio-activity, good uniformity, and high batch-to-batch consistency, making them ideal for CAR-T research. Sino Biological’s protein expression platform allows for customized services, including multiple labeling approaches such as FITC, PE, APC, and other fluorescent dyes.
In addition, Sino Biological has developed pre-labeled and experimentally validated biotinylated recombinant proteins. These proteins feature biotinylation at a single lysine residue within the Avi-tag, a 15 amino acid peptide. This approach ensures that the protein’s bioactivity remains unchanged, eliminating any interference. The binding between biotin and streptavidin/avidin (SA) is highly specific and sensitive, making it an excellent tool for detecting the positive rate of CAR expression. This eliminates the issues of heterogeneity and impaired function often associated with chemical biotinylation.
Overall, Sino Biological provides a comprehensive solution for CAR-T quality control, offering fluorescent-labeled target proteins and biotinylated recombinant proteins that facilitate efficient and accurate detection of CAR expression.
Below are a list of fluorescent labelled, biotin labelled, and unconjugated proteins.
Fluorescent-Labeled Target Proteins
Cat# | Protein | Species | Conjugate | Expression host | Tag |
---|---|---|---|---|---|
10620-H03H-P | BCMA | Human | PE | HEK293 | His & hFc |
12238-HCCH-P | CD33 | Human | PE | HEK293 | - |
10818-H08H-P | CD38 | Human | PE | HEK293 | His |
Biotin-labeled Target Proteins
Cat# | Protein | Species | Expression host | Tag | Purity |
---|---|---|---|---|---|
10818-H27H-B | CD38 | Human | HEK293 | His & AVI | >95% |
10673-H27H-B | NCAM1 | Human | HEK293 | His & AVI | >95% |
29662-H27H-B | EGFR | Human | HEK293 | His & AVI | >95% |
10679-H27H-B | ULBP1 | Human | HEK293 | His & AVI | >95% |
12143-H27H-B | ULBP2 | Human | HEK293 | His & AVI | >95% |
13926-H27H-B | EPHA2 | Human | HEK293 | His & AVI | >95% |
10692-H27H-B | c-MET | Human | HEK293 | His & AVI | >95% |
11027-H27H-B | CD5 | Human | HEK293 | His & AVI | >95% |
11958-H41H-B | CD22 | Human | HEK293 | hFc & AVI | >90% |
10350-H08H-B | IL13RA2 | Human | HEK293 | His | >95% |
10012-H08H-B | VEGFR2 | Human | HEK293 | His | >95% |
11077-H08H-B | CEACAM5 | Human | HEK293 | His | >95% |
11880-H08H-B | CD19 | Human | HEK293 | His | >90% |
12238-H08H-B | CD33 | Human | HEK293 | His | >90% |
10777-H08H-B | CD30 | Human | HEK293 | His | >90% |
29662-H08B-B | EGFR | Human | Baculovirus-Insect | His | >90% |
15877-H07H-B | PSMA | Human | HEK293 | His | >90% |
10088-H08H-B | Glypican-3 | Human | HEK293 | His | >85% |
10464-H07H-B | FAP | Human | HEK293 | His | >85% |
10084-H02H-B | PD-L1 | Human | HEK293 | hFc | >95% |
10694-H02H-B | EpCAM | Human | HEK293 | hFc | >90% |
13128-H01H-B | Mesothelin | Human | HEK293 | hFc | >85% |
11007-H34E-B | CD20 | Human | E. coli | TrxA | >85% |
13968-HCCH1-B | ROR1 | Human | HEK293 | - | >95% |
10004-HCCH-B | HER2 | Human | HEK293 | - | >95% |
Unconjugated Target Proteins
Cat# | Protein | Species | Expression host | Tag | Purity | Bioactivity |
---|---|---|---|---|---|---|
11880-H08H | CD19 | Human | HEK293 | C-His | >90% | active |
11958-h08h | CD22 | Human | HEK293 | C-His | >95% | active |
11958-HNAH | CD22 | Human | HEK293 | Native | >95% | - |
10777-H08H | CD30 | Human | HEK293 | C-His | >95% | active |
10818-H32H | CD38 | Human | HEK293 | N-His & FLAG | >93% | - |
10012-h02h1 | VEGFR2 | Human | HEK293 | C-human IgG1-Fc | >95% | active |
13926-h20b1 | EPHA2 | Human | Baculovirus-Insect | N-GST & His | >95% | active |
11028-h08h | CD7 | Human | HEK293 | C-His | >95% | active |
29662-h02b | EGFR | Human | Baculovirus-Insect | C-human IgG1-Fc | >95% | active |
30025-hnah | CLDN18 | Human | HEK293 | Native | >90% | active |
10088-h08h | Glypican-3 | Human | HEK293 | C-His | >87% | active |
10692-H20B1 | c-MET | Human | Baculovirus-Insect Cells | N-GST & His | >90% | active |
10107-h08h | CA9 | Human | HEK293 | C-His | >95% | active |
10084-h05h | PD-L1 | Human | HEK293 | C-mouse IgG1-Fc | >95% | active |
10084-HNAH | PD-L1 | Human | HEK293 | Native | >95% | - |
10121-H02H | IL1RAP | Human | HEK293 | C-human IgG1-Fc | >95% | - |
10518-H02H | CD123 | Human | HEK293 | C-human IgG1-Fc | >95% | - |
10377-H08H | PD-1 | Human | HEK293 | C-His | >95% | active |
10679-h03h | ULBP1 | Human | HEK293 | C-human IgG1-Fc & His | >95% | active |
12143-H08H | ULBP2 | Human | HEK293 | C-His | >97% | - |
15877-h07h | PSMA | Human | HEK293 | N-His | >95% | active |